Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAME COVID study of clarithromycin for non-oxygen-requiring COVID-19 pneumonia
jRCTs071210011Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of clarithromycin in coronavirus pneumonia (3 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Days required to improve clinical symptoms by 50% or more from baseline. Started May 2021; status: completed.
02
Drugs
clarithromycin
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on jRCTs071210011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210011.